"ChemRar" is a unique for Russia, non-state innovation business-incubator of technology companies, working in the field of "live systems". The main mission of ChemRar is development and launch to market of the original medical products based on the latest "post-genomics" technologies for treating cancer, infectious, cardiovascular disease, central nervous system diseases and metabolic disorders. On the basis of modern technological organizations "ChemRar" carries out a full cycle of preclinical and clinical development of new pharmaceutical compounds, starting with the identification of relevant biological targets for high-throughput screening, synthesis and testing of new molecules and formulations and finishing with the manufacturing of new drugs.

Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry.
Founded in August 2008 and headquartered in San Diego, California Avineuro is managed by seasoned professionals experienced in drug discovery and development. By acquiring lead compounds through collaborations and partnerships, Avineuro plans to develop novel products and extend the reach of marketed compounds for indications with a significant commercial potential.
Avineuro emphasizes a rational approach that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

iDialog was established in 2006 as an innovative biopharma start up. It received over USD$3M of seed investment from Torrey Pines Investment in 2007 and subsequently won the research partnership award of over USD$3 from the Russian Federal Agency of Science and Innovation for development of novel anti-infective agents to match unmet needs in Russia. iDialog conducted and continues the broad program to discover novel therapies for Tuberculosis, hepatitis C and Influenza, in partnership with Moscow State University and other academic organizations. In 2008 iDialog established the R&D collaboration with ChemDiv's Chemical Diversity Research Institute for discovery and development of novel small molecule anti-infective agents, which is extended to 2011.

Viriom is a young and innovative company, established in 2009 at the ChemRar High Tech Center for development of targeted drugs to treat HIV / AIDS. Viriom plans to conduct scientific research in Russia using the experience and knowledge of the Russian scientists. The company is partnering – among others – with Chemical Diversity Research Institute on preclinical studies of molecules, "Drug Technologies" on development of complete dosage forms, and the Moscow Center for HIV/AIDS Prevention.

Afraxis is discovering and developing drugs to treat diseases of the central nervous system, including schizophrenia, Alzheimer's disease, Fragile X syndrome and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines. Afraxis is leveraging this discovery to develop drug treatments that control dendritic spine function. The company's lead program targets PAK, a protein that regulates the development and activity of dendritic spines, creating therapies that actually modify the disease rather than just treat symptoms. Modifying the disease produces beneficial changes at the cellular and behavioral level, creating new hope for patients.

ChemRar Pharma, Moscow, Russia, develops inhibitors of developmental pathways and stem cell modulators for multiple oncology indications.

Partners